Open access
A Novel Nogo‐A Receptor Antagonist Peptide Impedes Alzheimer's Disease Pathology by Nogo‐A/NgR/ROCK Signaling Pathway
Zheng Zhang
Hui-Min Tan
Fang Shi
Jia-Jia Dai
Weilong Ding
Junliang Li
Yu-Ke Wang
Rui Yang
Xinke Xu
Cheng Chen
Fei Xiao
Li-An Huang
Xiaoyan Liu
Rui Liao
Li Yan
Medicine
Abstract
To evaluate the therapeutic effects of NAP2, a novel NgR1 antagonist peptide, on Alzheimer's disease (AD) pathology and to determine whether inhibition of the Nogo‐A/NgR1/ROCK signaling axis can ameliorate neurodegenerative alterations in APP/PS1 mice.